[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":387},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,42,70,106,128,155,177,198,220,244,283,321,348,366],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100053863",false,"NCT07698314","A Pilot Study Assessing Myokines During an EXErcise Regimen After Treatment for Breast Cancer","Myo-EXERTBC: A Pilot Study Assessing Myokines During an EXErcise Regimen After Treatment for Breast Cancer","Myo-EXERTBC","Inclusion Criteria:\n\n1. Age 20-89 years\n2. Women prescribed exercise as a SOC\n3. Women with a biopsy proven diagnosis of ductal carcinoma in situ (DCIS) or invasive carcinoma of the breast\n4. Women must have undergone treatment for breast cancer, including one or more of the following: surgery, radiation therapy, chemotherapy, immunotherapy, or hormonal therapy. Women undergoing active chemotherapy are not allowed on study. Immunotherapy or targeted agent usage is allowed.\n5. Women with \\> 3 months of resistance training experience under expert guidance at the Allegheny Health Network Exercise Oncology Center\n\nExclusion Criteria:\n\n1. Any current treatment with cytotoxic chemotherapy for breast cancer\n2. Inability to safely engage in group sessions of resistance training as deemed by study PI\n3. Severe arthritic, joint, cardiovascular, or musculoskeletal condition deemed by PI to be unsafe to engage in resistance training\n4. Pregnant women\n5. Males","FEMALE","20 Years","89 Years",{"count":20,"type":21},21,"ESTIMATED","INTERVENTIONAL",[24],"NA","In this pilot study, the investigators will assess the changes in myokine production based on several different exercise regimens.",[27,28],"Cancer","Breast Cancer","NOT_YET_RECRUITING","2026-07-07",{"date":32,"type":33},"2026-07-13","ACTUAL",{"date":35,"type":21},"2026-06",{"date":37,"type":21},"2028-06",{"name":39,"class":40},"Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)","OTHER",1,{"id":43,"slug":4,"hasResults":10,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":10,"sex":48,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":41},"100389684","NCT04354077","Deep Brain Stimulation Effects In Patients With Opioid Use Disorder","Pilot Study to Evaluate Deep Brain Stimulation (DBS) of the Nucleus Accumbens (NAc) for Patients With Treatment-refractory Opioid Use Disorder","Inclusion criteria\n\n1. Male and females age ≥ 22 years with diagnosis of opioid use disorder (OUD) based on Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) with at least a 5-year history\n2. OUD must be the primary disorder\n3. History of ongoing or previous opioid use, relapse, and\u002For cravings, despite attempts at, or attendance in, at least two different treatment modalities. These modalities may include: Comprehensive Opioid Addiction Treatment (COAT), intensive outpatient COAT, residential treatment, inpatient treatment, alternative to intensive outpatient programs, Drug Dependence Unit programs, medication-assisted treatment (MAT), medication assisted recovery (MAR), inpatient or outpatient rehabilitation, detox programs, Narcotics Anonymous, individual or group therapy, Partial Hospitalization Programs (PHP), Sober living homes, or similar interventions.\n4. Self-reports ongoing opioid cravings.\n5. Has completed a neuro-psychological evaluation to the satisfaction of a neuropsychologist\n6. Has completed a psychiatric evaluation to the satisfaction of a psychiatrist\n7. Has had a brain MRI performed and reviewed by neurosurgeon with no contraindication for DBS procedure identified\n8. Platelet count \\> 125,000 per cubic mm and prothrombin time (PT) and partial thromboplastin time (PTT) within normal limits\n9. Negative blood cultures to rule out bacteremia\n\nExclusion criteria\n\n1. Prior brain surgery\n2. Baseline assessment on the Hamilton Depression Rating Scale (HAMD) of greater than 17 or moderate risk of suicide based upon a score of 3 or greater on the Columbia Suicide Severity Scale, unless clinical judgment indicates that the individual is appropriate for inclusion despite these scores.\n3. History of uncontrolled or persistent seizures\n4. Suspected dementia based on neuropsychological screening or Mini Mental State Exam (MMSE) Score \\\u003C 25\n5. Contraindications for MRI:\n\n   1. Presence of implanted electrical stimulation device or other implanted metal devices (excluding dental braces).\n   2. Claustrophobia\n   3. Body weight exceeding limit of the machine (180 kg\u002F400 lb)\n6. Females who are pregnant or nursing. Female subjects of child-bearing potential must have a negative pregnancy test during the pre-op phase and must agree to utilize adequate birth control throughout the trial and for at least 30 days following trial completion.\n7. Coagulopathy secondary to chronic need for anticoagulation medicine (e.g. warfarin) or anti-platelet medication (e.g. aspirin or clopidogrel)\n8. Diagnosis of neurological disorders (e.g. multiple sclerosis, Parkinson's disease, and stroke)\n9. Severe brain atrophy or presence of subdural hygromas or subdural hematomas on brain MRI\n10. Any evidence of underlying endocarditis.\n11. Primary language other than English\n12. Have any other medical condition that, in the opinion of the Investigator, makes the subject unsuitable for enrollment.","ALL","22 Years","65 Years",{"count":52,"type":21},3,[24],"This is a pilot study to evaluate the safety and efficacy of deep brain stimulation (DBS) of the nucleus accumbens (NAc) as adjunctive treatment for treatment-refractory opioid use disorder. This study will include 3 individuals with opioid use disorder and relapsing opioid use despite active participation in a drug addiction treatment program.",[56],"Opioid-use Disorder",[58,59,60],"Deep Brain Stimulation","Addiction","Nucleus Accumbens","RECRUITING","2026-06-17",{"date":64,"type":33},"2026-06-18",{"date":66,"type":33},"2022-02-07",{"date":68,"type":21},"2030-01",{"name":39,"class":40},{"id":71,"slug":4,"hasResults":10,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":10,"sex":48,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":83,"conditions":84,"keywords":89,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":41},"100627006","NCT07443020","Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors","Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors: A Phase I Trial (FAST TILS 2)","RIOT 4B","Inclusion Criteria:\n\n1. Patients with symptomatic, biopsy-proven malignant to the pleura, or mesothelioma with pleural effusions. Patients must have received and be refractory to available standard of care (SOC) therapy specific to their cancer type and must have exhausted or failed available standard of care with clinical benefit.\n2. Patients will be ≥ 18 and \\\u003C 80 years of age.\n3. Female patients of childbearing potential must have a negative urine or serum pregnancy test and if sexually active must use an acceptable method of contraception, including abstinence, a barrier method (diaphragm or condom), an injectable contraceptive (such as Depo-Provera), or an oral contraceptive. Active contraception should continue for at least 12 months after ACT administration.\n\n   Male participants must be willing to practice birth control from the time of enrollment on this study and for 4 months after receiving the preparative regimen.\n4. Cardiac ejection fraction ≥ 0.45 by MUGA or echocardiography.\n5. No requirement for supplemental oxygen and no dyspnea immediately after effusion drainage.\n6. ECOG Performance Status 0 or 1.\n7. Patients must have an expected survival \\> 12 weeks.\n8. Patients must be able to comprehend the risks and methods used in this clinical trial and independently consent to participate.\n9. Patients must consent to collection of demographic and clinical data.\n\nExclusion Criteria:\n\n1. Infection with HIV and active viral replication. Patients with an undetectable viral load on Anti-retroviral Therapy (ART) can be considered for participation on this protocol.\n2. Infection with hepatitis B and active viral replication.\n3. Infection with hepatitis C and active viral replication.\n4. Patients currently being treated for bacterial, fungal or viral infection.\n5. Documented myocardial infarction within 6 months of study participation and\u002For symptomatic coronary artery or valvular disease or uncontrolled arrhythmia.\n6. Investigational drug use within 30 days before effusion collection.\n7. Cytotoxic anti-cancer or radiation therapy administration within 2 weeks of effusion collection. The exclusion does not apply to patients receiving monoclonal antibody therapy targeting immune checkpoint molecules.\n8. Corticosteroid therapy \\> 10 mg of prednisone (biological equivalent) daily within 2 weeks before effusion collection.\n9. Immunosuppressive therapy that cannot be stopped for 4 weeks prior to effusion collection as deemed by the prescribing physician.\n10. Laboratory abnormalities that indicate clinically significant hematological, hepatobiliary, or renal disease:\n\n    AST\u002FSGOT \\> 2.0 times the upper limit of normal ALT\u002FSGPT \\> 2.0 times the upper limit of normal Total bilirubin \\> 2.0 times the upper limit of normal, unless patient has Gilbert Syndrome (\\>3.0 times the upper limit of normal) Hemoglobin \\\u003C 8 gm\u002FdL or dependent upon transfusion to maintain ≥ 8 gm\u002FdL White blood cell count \\\u003C 2,000\u002Fmm3 Platelet count \\\u003C 100,000\u002Fmm3 or dependent upon transfusion to maintain ≥ 100,000 mm3 Creatinine \\> 2.0 times the upper limit of normal or calculated creatinine clearance ≤ 40 mL\u002Fmin.\n11. Pregnant or lactating females.\n12. Prior solid organ transplantation\n13. Patients who, in the opinion of the Investigator, will be non-compliant with study schedules or procedures.\n14. Patients who belong to a vulnerable population such as the homeless, the developmentally disabled and prisoners or have any condition that impairs their ability to provide informed consent or comply with study schedules or procedures.\n15. Patients with documented anaphylaxis as a result of penicillin allergy.","18 Years","79 Years",{"count":80,"type":21},10,[82],"PHASE1","This research study aims to evaluate the safety and effectiveness of a novel immunotherapy, Fast TIL, an Adoptive Cellular Therapeutic (ACT), to fight cancer that has spread to the pleura or pleural mesothelioma. The ACT product is created at AHN West Penn using the participant's pleural infiltrating T-cells (PIT). It is administered through a pleural catheter along with the drug Interleukin-2 (IL-2). Based on previous research it is believed that it may help fight the tumor and relieve symptoms.\n\nAs a participant, their pleural fluid will be collected and the PIT cells will be isolated and expanded in the lab to create the ACT product. Before receiving the ACT product through their pleural catheter, they will undergo outpatient lymphodepleting chemotherapy. LDC is a standard procedure for many approved immunotherapy treatments Following the infusion, they'll receive IL-2 through the catheter for two days to stimulate the expanded PIT cells.\n\nThe active treatment phase lasts about three weeks, with follow-up visits over five years at AHN West Penn Hospital, potentially requiring a hospital stay of up to six days. Blood samples will be taken to monitor their response. As this is a first-in-human study, treatment carries an unknown risk up to and including death from toxicity. However, the risks of similar immunotherapy treatments are well documented.",[85,86,87,88],"Malignant Pleural Effusion","Malignant Mesothelioma","Pleural Effusion, Malignant","Metastasis to Pleura",[90,91,92,93,94,95,96,97],"metastasis to pleura","pleural infiltrating T cells","CliniMACS Prodigy","malignant mesothelioma","pleural effusion, malignant","Adoptive Cellular Therapeutic","immunotherapy","autologous tumor infiltrating lymphocytes (TIL)","2026-04-01",{"date":100,"type":33},"2026-04-07",{"date":102,"type":21},"2026-05",{"date":104,"type":21},"2038-03",{"name":39,"class":40},{"id":107,"slug":4,"hasResults":10,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":112,"sex":16,"minAge":77,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":115,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":41},"100408353","NCT04597372","Impact of Tamsulosin on Post-Operative Urinary Retention Following Pelvic Reconstructive Surgery","The Impact of Tamsulosin on Duration of Post-Operative Urinary Retention in Women Undergoing Pelvic Reconstructive Surgery- A Double Blind, Randomized, Placebo-Controlled Study","Inclusion Criteria:\n\n* 18 years or older\n* willing and able to provide informed consent\n* postoperative urinary retention as defined by a failed RGVT prior to hospital discharge\n* Ability to speak and read English\n* Tolerate pill ingestion\n\nExclusion Criteria:\n\n* allergy\u002Fintolerance to Tamsulosin or sulfa drugs\n* preoperative history of urinary retention as defined by preoperative post void residual of \\>150mL\n* current use of alpha antagonist medication for hypertension\n* severe dementia\n* end stage renal or liver disease\n* history of severe heart failure or major cardiovascular event in the last 6 months",true,{"count":114,"type":21},154,[116],"PHASE2","The objective of the study is to determine the effectiveness of postoperative Tamsulosin in reducing the duration of acute postoperative urinary retention (POUR) following pelvic reconstructive surgery through a double blind, randomized placebo-controlled trial.",[119],"Urinary Retention Postoperative","2026-03-18",{"date":122,"type":33},"2026-03-20",{"date":124,"type":33},"2021-11-03",{"date":126,"type":21},"2026-12",{"name":39,"class":40},{"id":129,"slug":4,"hasResults":10,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":10,"sex":48,"minAge":77,"maxAge":18,"enrollmentInfo":134,"targetDuration":4,"studyType":22,"phases":136,"briefSummary":138,"conditions":139,"keywords":145,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":4},"100626011","NCT07430085","Post-Operative Pain Relief: Zynrelef or Periarticular Injections in RATKA","Postoperative Pain Outcomes After Use of Bupivacaine-Meloxicam Extended-Release Solution in Robot Assisted Total Knee Arthroplasty: A Prospective Study","Inclusion Criteria:\n\nMales or females aged 18-89 years\n\nDiagnosed with knee osteoarthritis requiring surgical intervention\n\nIndicated for unilateral RATKA\n\nExclusion Criteria:\n\nPediatric, pregnant, or incarcerated patients\n\nBMI of more than 45 kg\u002Fm2\n\nProlonged opioid use history of \\>5 mg\u002Fday for \\>1 month\n\nHistory of contralateral TKA \\\u003C2 years prior to the index TKA\n\nType 1 Hypersensitivity to NSAIDs or local anesthetics\n\nDiagnosis of severe renal disease",{"count":135,"type":21},150,[137],"PHASE4","Prospective Cohort of patients who are scheduled for a Robot Assisted Total Knee Arthroplasty (RATKA). A prospective survey of patient reported outcome measures (Numeric Rating Scale) will be obtained postoperatively of 72 hours, as well as at the postoperative opioid consumption after 72 hours.",[140,141,142,143,144],"Periarticular Block","Osteoarthritis (OA)","Osteoarthritis (OA) of the Knee","Pain After Surgery","Knee Arthroplasty, Total",[146],"Zynrelef","2026-02-24",{"date":149,"type":33},"2026-02-27",{"date":151,"type":21},"2026-01-31",{"date":153,"type":21},"2028-02-28",{"name":39,"class":40},{"id":156,"slug":4,"hasResults":10,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":162,"targetDuration":4,"studyType":164,"phases":4,"briefSummary":165,"conditions":166,"keywords":167,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":41},"100594779","NCT07023887","Prospective Study of EXErcise Regimens After Treatment for Breast Cancer for Hypertrophy and Conditioning","EXERT-BCHC: Prospective Study of EXErcise Regimens After Treatment for Breast Cancer for Hypertrophy and Conditioning","EXERT-BCHC","Inclusion Criteria:\n\n1. Age 20-89 years\n2. Women prescribed exercise as a Standard of Care\n3. Women with a biopsy proven diagnosis of ductal carcinoma in situ (DCIS) or invasive carcinoma of the breast\n4. Women must have undergone treatment for breast cancer, including one or more of the following: surgery, radiation therapy, chemotherapy, immunotherapy, or hormonal therapy.\n5. Women undergoing active chemotherapy are not allowed on study. Immunotherapy or targeted agent usage is allowed.\n6. Women with \\> 6 months of resistance training experience under expert guidance by a CSCS\n\nExclusion Criteria:\n\n1. Any current treatment with cytotoxic chemotherapy for breast cancer\n2. Inability to safely engage in group sessions of resistance training as deemed by study Pl\n3. Severe arthritic, joint, cardiovascular, or musculoskeletal condition deemed by Pl to be unsafe to engage in resistance training\n4. Beta blocker or GLP-1 inhibitor medications\n5. Pregnant women\n6. Males",{"count":163,"type":21},15,"OBSERVATIONAL","This study investigates the impact of four standard of care, monitored group exercise regimens (resistance training) on conditioning and hypertrophy in women previously treated for breast cancer. The study will compare two conditioning regimens (6-12-25 and 8x8) and two hypertrophy regimens (5\u002F5\u002F5 cluster sets and double training) to assess changes in VO2 max, muscle mass, and fat mass.",[27,28],[168],"exercise","2026-02-02",{"date":171,"type":33},"2026-02-04",{"date":173,"type":33},"2025-05-21",{"date":175,"type":21},"2026-10-15",{"name":39,"class":40},{"id":178,"slug":4,"hasResults":10,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":184,"targetDuration":4,"studyType":22,"phases":186,"briefSummary":187,"conditions":188,"keywords":189,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":41},"100582064","NCT06858449","Resistance Training and Post Workout Protein to Improve Body Composition During Neoadjuvant Chemotherapy for Breast Cancer","NeoChemoPRT: A Randomized Study of Resistance Training and Post-Workout Protein to Improve Body Composition During Neoadjuvant Chemotherapy for Breast Cancer","NeoChemoPRT","Inclusion Criteria:\n\n1. Age 20-89 years\n2. Women with a biopsy proven diagnosis of invasive carcinoma of the breast.\n3. Women must undergo neoadjuvant chemotherapy for breast cancer treatment prior to surgery\n4. Must be able to read and understand English and consent for themselves.\n\nExclusion Criteria:\n\n1. Inability to get up and down off the ground or squat body weight\n2. Inability to safely engage in group exercise sessions as deemed by study PI\n3. Severe arthritic, joint, cardiovascular, musculoskeletal, or any other condition deemed by PI to be unsafe to engage in resistance training\n4. Lactose intolerance\n5. Cow's milk or whey protein allergy\n6. Pregnant women\n7. Males",{"count":185,"type":21},30,[24],"In this study, the investigators hypothesize that a high dose of post-workout protein nutrition regimen focused on food quality and an observed exercise regimen utilizing high-load resistance training initiated during or after cancer treatment will improve body composition and functional capacity.",[27,28],[168,190],"resistance training",{"date":192,"type":33},"2026-02-03",{"date":194,"type":33},"2025-01-02",{"date":196,"type":21},"2027-03",{"name":39,"class":40},{"id":199,"slug":4,"hasResults":10,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":204,"targetDuration":4,"studyType":22,"phases":205,"briefSummary":206,"conditions":207,"keywords":210,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":214,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":41},"100524957","NCT06115486","EXERT-BCH Exercise Regimen to Improve Muscle Mass After Treatment of Breast Cancer","EXERT-BCH: Prospective Study of EXErcise Regimens After Treatment for Breast Cancer to Improve Hypertrophy","Inclusion Criteria:\n\nAge 20-89 years\n\n* Women with a biopsy proven diagnosis of ductal carcinoma in situ or invasive carcinoma of the breast\n* Women must have undergone treatment for breast cancer, including one or more of the following: surgery, radiation therapy, chemotherapy, immunotherapy, or hormonal therapy. Women undergoing active chemotherapy are not allowed on study. Immunotherapy or targeted agent usage is allowed.\n\nExclusion Criteria:\n\n* Any current treatment with cytotoxic chemotherapy for breast cancer\n* Inability to safely engage in group sessions of resistance training as deemed by study PI\n* Severe arthritic, joint, cardiovascular, or musculoskeletal condition deemed by PI to be unsafe to engage in resistance training",{"count":185,"type":21},[24],"The purpose of this research study is to evaluate the outcomes of two standard of care group exercise regimens to increase muscle mass in women who have been treated with breast cancer.",[28,208,209],"Breast Carcinoma in Situ","Breast Cancer Female",[27,211,212,213],"Carcinoma in Situ","Hypertrophy","Exercise",{"date":171,"type":33},{"date":216,"type":33},"2024-01-09",{"date":218,"type":21},"2027-01",{"name":39,"class":40},{"id":221,"slug":4,"hasResults":10,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":10,"sex":48,"minAge":77,"maxAge":226,"enrollmentInfo":227,"targetDuration":4,"studyType":22,"phases":229,"briefSummary":230,"conditions":231,"keywords":233,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":243,"locationsCount":41},"100392310","NCT04388332","ACDF Using Structural Allograft vs. Tritanium C","Comparison of Clinical Outcomes Following ACDF With Instrumentation Using Structural Allograft vs. Tritanium C","Inclusion Criteria:\n\n1. Males or females ≥18 years of age, ≤ 80 years of age\n2. Subject is skeletally mature\n3. Subject is diagnosed with degenerative disc disease (DDD) at one level or two contiguous levels from the C2 -T1 disc\n4. Subject has received six weeks of non-operative therapy i.e. injections, physical therapy, oral steroids\n5. Subject understands the conditions of enrollment and is willing to sign and date the Informed Consent (Prospective study)\n6. Subjects that will prospectively undergo one or two level anterior cervical discectomy and fusion with Tritanium C (Prospective study)\n7. Subjects that underwent one or two level anterior cervical discectomy and fusion with either standard of care structural allograft bone at any AHN facility from 01\u002F01\u002F2016 to 08\u002F14\u002F2023 (Retrospective study) • Note that these patients will be followed for a maximum of one year (up to 08\u002F14\u002F2024 for a patient enrolled at the end of this inclusion period)\n\nExclusion Criteria:\n\nPatients may not be enrolled in the study if any of the following exclusion criteria are present:\n\n1. Presence of an infection systemic or local\n2. Presence of marked local inflammation\n3. Subject has any abnormality present which affects the normal process of bone remodeling including, but not limited to, severe osteoporosis involving the spine, bone absorption, osteopenia, primary or metastatic tumors involving the spine, active infection at the site or certain metabolic disorders affecting osteogenesis\n4. Use of bone growth stimulator\n5. Subject has prior fusion at the levels to be treated\n6. Subject has any neuromuscular deficit\n7. Subject has any condition of senility, mental illness, or substance abuse\n8. Subject has any other medical or surgical condition which would preclude the potential benefit of spinal implant surgery in the judgement of the PI\n9. Subject has rapid joint disease, bone absorption, osteopenia, osteomalacia, and\u002For osteoporosis. Subject is pregnant or plans to become pregnant during the course of the study.\n10. BMI≥40 kg\u002Fm2\n11. Subject uses chronic corticosteroids\n12. Subjects with current active psychiatric diagnosis or a personality disorder likely to interfere with the study\n13. Subjects who smoke and do not plan to quit\n14. Mental or neuromuscular disorder which would create an unacceptable risk of fixation failure or complications in postoperative care\n15. Subject has any open wounds\n16. Subject has inadequate tissue coverage over the operative site\n17. Subject may be sensitive to titanium materials\n18. Subject is missing 6 and\u002For 12 month clinical or radiographic follow-up (Retrospective study)","80 Years",{"count":228,"type":21},60,[24],"This is an observational, descriptive, prospective and retrospective data collection study. The purpose of this study is to observe radiographic outcomes of patients who will undergo anterior cervical discectomy and fusion (ACDF) utilizing Tritanium C (Stryker Spine). The rate of fusion success and adverse events will be compared retrospectively to patients who underwent instrumented ACDF utilizing structural allograft bone with plates.",[232],"Degenerative Disc Disease",[234,235,236],"Tritanium C","Structural Bone Graft","Anterior Cervical Discectomy and Fusion","2025-11-13",{"date":239,"type":33},"2025-11-14",{"date":241,"type":33},"2020-08-20",{"date":126,"type":21},{"name":39,"class":40},{"id":245,"slug":4,"hasResults":10,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":249,"eligibilityCriteria":250,"healthyVolunteers":10,"sex":48,"minAge":77,"maxAge":18,"enrollmentInfo":251,"targetDuration":4,"studyType":22,"phases":253,"briefSummary":254,"conditions":255,"keywords":266,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":282,"locationsCount":41},"100572340","NCT06731998","Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery","Evaluating Optimal Perioperative Pain Management: A Prospective Randomized Control Trial of Laparoscopic Transversus Abdominis Plane Block With Local Anesthetic, Laparoscopic Transversus Abdominis Plane Block Alone, and Local Anesthetic Alone in Minimally Invasive Oncologic Surgery","LapTAP","Inclusion Criteria:\n\n1. Male and female patients age ≥ 18 - 89\n2. Patients scheduled for elective (clinically indicated) hepatic, gastric, biliary, pancreatic, gynecologic, colorectal, other GI Minimally invasive oncologic surgery.\n3. Patients who have provided informed consent to participate in the study.\n4. Patients with an American Society of Anesthesiologists (ASA) physical status classification of I, II, or III.\n5. Patients undergoing procedures anticipated to last more than 1 hour but less than 8 hours.\n6. Patients able to understand and self-report pain using the designated pain Visual Analog Scale\n\nExclusion Criteria:\n\n1. Patients age less than 18 or ≥ 90\n2. Pre-existing hepatic dysfunction, cirrhosis\n3. Patients with an ASA classification of IV or higher.\n4. Patients with chronic pain disorders or on long-term opioid or analgesic therapy.\n5. Patients with known contraindications to the study drugs or procedures (e.g., allergy to LA or contraindications to LapTAP).\n6. Patients with cognitive impairments or psychiatric conditions that could interfere with pain assessment or understanding of informed consent.\n7. Patients unable to understand the language in which consent and study-related information are provided (The study and the study-related information will be in the English Language)..\n8. Patients who have undergone major surgery within the last 6 months.\n9. Female patients who are pregnant.\n10. Patients currently enrolled in another clinical trial that might interfere with the outcome measures of this study.",{"count":252,"type":21},48,[24],"This is a research study to evaluate the effectiveness of 3 different types of routine pain management regimens used during clinically indicated, minimally invasive oncologic (cancer) surgery. This project is considered \"Research\" and participation is voluntary. Upon enrollment in this study, the research team will collect data from the patient's medical records. The patient will undergo all of the normal testing and procedures required pre-operatively (standard of care). The study team will then randomly assign the patient (like a flip of a coin) to one of three different study arms for pain management during surgery:\n\n1. Laparoscopic Transversus Abdominis Plane Block (LapTAP) with Local Anesthetic (LA)\n2. Laparoscopic Transversus Abdominis Plane Block (LapTAP) only\n3. Local Anesthetic (LA) only The patient will receive standard pre- and post-operative care according to clinical guidelines (routine care). The study team will collect information from the patient's medical record for the first 24 hours after their surgery and upon discharge. This information will include pain scores, amount of medication required, any side effects the patient may have experienced, and satisfaction with pain control. Participation in the study will end upon discharge from the hospital.",[256,27,257,258,259,260,261,262,263,264,265],"Oncologic Surgery","Cancer Surgery","Hepatic Cancer","Gastric (Cardia, Body) Cancer","Biliary Tract Cancer","Pancreatic Cancer Resectable","Gynecologic Cancers","Gastrointestinal Cancers","Colorectal Cancer","Minimally Invasive Surgical Procedures",[267,268,269,270,271,272,273,274,275],"Laparoscopic Transversus Abdominis Plane Block","Local Anesthetic","Laparoscopic Surgical Procedure","pain management","cancer","cancer surgery","oncologic surgery","perioperative pain management","minimally invasive surgical procedures","2025-09-15",{"date":278,"type":33},"2025-09-18",{"date":280,"type":33},"2025-02-05",{"date":126,"type":21},{"name":39,"class":40},{"id":284,"slug":4,"hasResults":10,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":288,"eligibilityCriteria":289,"healthyVolunteers":10,"sex":48,"minAge":77,"maxAge":290,"enrollmentInfo":291,"targetDuration":4,"studyType":22,"phases":293,"briefSummary":294,"conditions":295,"keywords":308,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":41},"100593065","NCT07001592","Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors","A Phase I Dose-Escalation Trial of vvDD-hIL2-2-RG-1 (Vaccina Virus Double Deleted) Administered by Intra-tumoral (IT) Injection for Metastatic Gastrointestinal and Peritoneal Tumors","RIOT3","Inclusion Criteria:\n\n1. Males or females age, 18 to \\\u003C 70 years at the time of consent\n2. Histologically confirmed metastases from gastrointestinal tumors with molecular determinants for MSI and KRAS.\n3. For microsatellite stable (MSS) tumors, subjects must have failed (or be ineligible for) standard 1st and 2nd line chemotherapy. For microsatellite instability-high (MSI-H) tumors, subjects must also have failed (or be ineligible for) systemic immunotherapy.\n4. Karnofsky Performance Status (KPS) of \\> 70\n5. Anticipated survival of at least 12 weeks.\n6. Written informed consent in accordance with national, local, and institutional guidelines obtained prior to any study procedures (subject or subject's legally authorized representative (LAR) must have the ability to understand and willingness to sign a written informed consent).\n7. Adequate bone marrow function: WBC \\> 2,000 and \\\u003C50,000 cells\u002Fmm3, ANC \\> 1,000 cells\u002Fmm3, hemoglobin \\>8 g\u002FdL, and platelet count \\>100,000 cells\u002Fmm3.\n8. Adequate renal function: serum creatinine level ≤ 2xULN\n9. Adequate liver function: Serum bilirubin \\\u003C 1.5 x ULN\n10. Acceptable coagulation status: INR \\\u003C ULN +15%. All patients must be able to suspend anticoagulant therapy for study specific biopsies and intra-tumoral injection.\n11. Women of childbearing potential (defined as all women physiologically capable of becoming pregnant) must have negative serum or urine pregnancy test.\n12. If sexually active, to prevent pregnancy and to prevent the spread of virus, subject must use an acceptable method of contraception as well as barrier contraception from screening through 6 weeks following study treatment with vvDD-hIL-2-RG-1.\n13. Subjects must be willing to comply with all study procedures, requirements, adhere to post-treatment care instructions and follow-up examinations.\n14. Have measurable disease based on RECIST 1.1 criteria.\n15. Have at least one tumor at least 1 cm in diameter amenable to safe intra-tumoral injection.\n\nExclusion Criteria:\n\n1. Pregnant or nursing an infant.\n2. Systemic corticosteroid or other immunosuppressive medication use within 2 weeks of the study treatment.\n3. Significant immunodeficiency (e.g. due to underlying illness and\u002For medication) in subject or household contacts (must be able to avoid household contact with immunodeficient person for 3 weeks).\n4. Clinically significant active infection or uncontrolled medical condition (e.g., pulmonary, neurological, cardiovascular, gastrointestinal, genitourinary) considered high risk for investigational new drug treatment, per investigator discretion.\n5. Active eczema or psoriasis or other inflammatory skin conditions\n6. Unstable cardiac disease which includes but is not limited to any of the following within 6 months prior to study entry: myocardial infarction (MI), unstable angina, congestive heart failure, myocarditis, ventricular arrhythmias diagnosed and requiring medication.\n\n   * New York Heart Association functional class III-IV heart failure on active treatment\n   * Pulse oximetry of \\\u003C 90% in room air at rest\n7. Subjects who have received radiation, chemotherapy or other potentially immunosuppressive therapy within 2 weeks prior to study screening and within 4 weeks prior to anticipated vvDD-hIL-2-RG-1 treatment.\n8. Experienced a severe systemic reaction or side-effect as a result of a previous smallpox vaccination.\n9. Subjects who, in the opinion of the Investigator, have a medical condition that would subject the subject to prohibitive risk by participation in this study, or who may be unable to safely complete the required tumor biopsies.\n10. Subjects with household contacts who are children \\\u003C 5 years old, have active eczema, psoriasis or other inflammatory skin conditions or have a significant immunodeficiency due to underlying illness (e.g. human immunodeficiency virus) and\u002For medication (e.g. systemic corticosteroids) will be excluded unless alternate living arrangements can be made during the subject's active dosing period and for three weeks following the study medication.\n11. Vaccination with a live virus in the previous 60 days prior to Day 0.\n12. Inability or unwillingness to give informed consent.\n13. Is unable or unwilling to comply with protocol follow-up requirements. -","69 Years",{"count":292,"type":21},18,[82],"This research study aims to evaluate the safety and determine the optimal dose of a new experimental drug, vvDD-hIL2 (vaccinia virus double-deleted human interleukin 2), in patients with advanced abdominal cancer. The study will involve three dose levels, with three to six patients enrolled at each level.\n\nvvDD-hIL2 is a genetically modified vaccinia virus, derived from the virus previously used for smallpox vaccination. The modification is intended to target and destroy tumors while minimizing harm to healthy tissues by stimulating the body's immune response.\n\nParticipants will receive an injection of vvDD-hIL2 directly into their abdominal tumors at AHN West Penn. The study team will monitor for side effects and assess tumor response to the treatment.\n\nActive participation will last up to two months, involving seven clinic visits and approximately four lab visits at AHN West Penn Hospital. Visits will include standard of care procedures as well as study-specific tests and exams. Most visits will last one to two hours, with some extending to two to three hours. The drug administration day will require a twelve-hour visit.\n\nEffectiveness and side effects will be evaluated through blood draws, oral swabs, urinalysis and tissue biopsies. Tissue samples will be used for genomic analysis and stored for potential future research. Data collected may also be used for future research purposes.\n\nPrevious human trials of vvDD-hIL2 have reported side effects such as pain, rash or inflammation at the injection site, low-grade fevers, flu-like symptoms, and fatigue. There is a rare risk of rash transmission to close contacts with skin openings, and information on limiting contact and managing rash development will be provided.",[296,297,298,299,300,301,302,303,304,305,306,307],"Gastric Neoplasms","Esophageal Cancer","Liver Cancer","Liver Metastasis","MSS-CRC","MSS","Gastric Adenocarcinoma","Peritoneal Cancer","Peritoneal Carcinoma","Peritoneal Metastases","MSI-H","Gastric Cancer",[309,310,96,311,312],"Oncolytic virus","vaccinia","intra-tumoral","intra-peritoneal","2025-06-02",{"date":315,"type":33},"2025-06-03",{"date":317,"type":33},"2025-05-06",{"date":319,"type":21},"2028-05",{"name":39,"class":40},{"id":322,"slug":4,"hasResults":10,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":326,"eligibilityCriteria":327,"healthyVolunteers":10,"sex":48,"minAge":77,"maxAge":18,"enrollmentInfo":328,"targetDuration":4,"studyType":22,"phases":330,"briefSummary":331,"conditions":332,"keywords":334,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":347,"locationsCount":41},"100517333","NCT06016179","Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer","Phase I Intra-patient Dose Escalation Study of the IL-6 Receptor Antagonist Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Pleural Effusion or Peritoneal Ascites Due to Metastatic Cancer","RIOT2","Inclusion Criteria:\n\n1. Males or females ages 18-89 years\n2. Female patients must have a negative pregnancy test and agree to use contraception. Female patients receiving tocilizumab should maintain adequate contraceptive measures during and for a minimum of 90 days after the last dose of tocilizumab. Male patients receiving tocilizumab should maintain adequate contraceptive measures during and for a minimum of 60 days after the last dose of tocilizumab.\n3. Biopsy-proven diagnosis of malignancy with cytologic or radiographic evidence of malignant pleural effusion or ascites\n4. Scheduled to undergo standard-of-care pleural or peritoneal drainage catheter placement\n5. ECOG 0-2\n6. Able to read and understand consent in English and provide informed consent\n\nExclusion Criteria:\n\n1. Pediatric patients\n2. Laboratory abnormalities that indicate clinically significant inflammatory process AST\u002FSGOT \\> 2 times the upper limit of normal ALT\u002FSGPT \\> 2 times the upper limit of normal Total bilirubin \\> 2 times the upper limit of normal Creatinine \\> 2.5 mg\u002FdL Hemoglobin \\\u003C 7 mg\u002FdL White blood cell count \\\u003C 3,000\u002F mm3 Platelet count \\\u003C 70,000\u002Fmm3 Absolute neutrophil cell count \\\u003C 2,000 per mm3\n3. ECOG \\> 3\n4. Subjects who are unable to comply with study procedures including travel for weekly outpatient clinic visits\n5. Pregnant and lactating women\n6. Active immunotherapy within 30 days; concurrent chemotherapy or targeted therapy is permitted but for patients with a history of prior immunotherapy, the most recent dose should be \\>30 days prior to the first treatment visit\n7. Investigational drug use within 30 days prior to first treatment dose\n8. History of systemic autoimmune disease (CRS, GCA, PJIA, RA, and SJIA)\n9. Patient with known hypersensitivity to tocilizumab (IL-6)\n10. Active infection\n11. Medical contraindication or history of adverse reaction to acetaminophen or diphenhydramine",{"count":329,"type":21},12,[82],"The purpose of this study to find out if tocilizumab can be safely infused into chest or abdominal cavities of patients with malignancy ascites (MA) or malignant pleural effusions (MPE). Patients will have a total of 4 doses, one dose administered each week. Each dose will be greater than the previous one.",[85,333],"Malignant Ascites",[85,333,335,336,337,338,339,340],"Tocilizumab","IL-6 receptor antagonist","peritoneal cavity","pleural cavity","intraperitoneal","intrapleural","2025-05-19",{"date":343,"type":33},"2025-05-22",{"date":345,"type":33},"2024-01-30",{"date":218,"type":21},{"name":39,"class":40},{"id":349,"slug":4,"hasResults":10,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":4,"eligibilityCriteria":353,"healthyVolunteers":10,"sex":48,"minAge":17,"maxAge":18,"enrollmentInfo":354,"targetDuration":4,"studyType":164,"phases":4,"briefSummary":355,"conditions":356,"keywords":357,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":41},"100562994","NCT06610396","Ex Onc SLED: a Study Utilizing a Weighted Sled for Horizontal Resistance Training","Ex Onc SLED: a Pilot Study Utilizing a Weighted Sled for Horizontal Resistance Training","Inclusion Criteria:\n\n1. Age 20-89 years\n2. Women of child-bearing potential must verbally confirm lack of pregnancy prior to enrollment. They should also consent to use adequate contraception during the course of the study.\n3. Participants must be determined capable of engaging in resistance training by exercise personnel and\u002For study PI and must be able to stand.\n4. Participants must complete an assessment by EOC staff and be determined safe to engage in the workout regimen by the study exercise personnel. Any individuals not deemed safe to participate in the basic EOC exercise program will be referred to physical therapy or elsewhere\n\nExclusion Criteria:\n\n1. Severe arthritic, joint, cardiovascular, or musculoskeletal condition that would interfere with exercise program\n2. Individuals deemed able to engage in more intense resistance training utilizing compound movements will not be eligible\n3. Pregnant women",{"count":185,"type":21},"This protocol seeks to analyze patient adherence and outcomes after monitored exercise sessions utilizing primarily weighted sled pushes and pulls for linearly progressed resistance training of individuals who have been diagnosed with cancer.",[27],[168,190],"2025-02-24",{"date":360,"type":33},"2025-02-26",{"date":362,"type":33},"2024-06-18",{"date":364,"type":21},"2026-09-18",{"name":39,"class":40},{"id":367,"slug":4,"hasResults":10,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":371,"eligibilityCriteria":372,"healthyVolunteers":10,"sex":48,"minAge":17,"maxAge":18,"enrollmentInfo":373,"targetDuration":375,"studyType":164,"phases":4,"briefSummary":376,"conditions":377,"keywords":378,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":379,"lastUpdatePostDateStruct":380,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":386,"locationsCount":41},"100522492","NCT06083324","EXErcise Regimen Designed to Improve Functional Mobility, Body Composition, and Strength After Treatment for Cancer","EXERT-C: Prospective Study of an EXErcise Regimen Designed to Improve Functional Mobility, Body Composition, and Strength After Treatment for Cancer","EXERT-C","Inclusion Criteria:\n\n1. Age 20-89 years\n2. Women of child-bearing potential must verbally confirm lack of pregnancy prior to enrollment. They should also consent to use adequate contraception during the course of the study.\n3. Participants must be determined capable of engaging in resistance training by exercise personnel and\u002For study PI\n4. Participants must complete an assessment by EOC staff and be determined safe to engage in the workout regimen by the study exercise personnel.\n5. Individuals not deemed safe to participate in the standard EOC exercise program will be referred to physical therapy or elsewhere\n\nExclusion Criteria:\n\n1\\. Severe arthritic, joint, cardiovascular, or musculoskeletal condition that would interfere with exercise program",{"count":374,"type":21},100,"3 Months","This protocol seeks to analyze patient outcomes of the standard of care, monitored group exercise regimen of high-load resistance training and functional exercises with compound movements under close supervision on individuals who have been treated for cancer.",[27],[168,190],"2025-02-19",{"date":381,"type":33},"2025-02-21",{"date":383,"type":33},"2023-02-03",{"date":385,"type":21},"2026-01-26",{"name":39,"class":40},""]